National Cancer Registry

Definition	A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives	- To measure cancer incidence - To describe cancer by time, place, persons and disease - To provide a national database for further epidemiological research
Case definition	Target cases are: - Incident cases by year of diagnosis - Malignant tumors confirmed by histopathology and/or hematology findings - Cancers of all sites
Sources of data	Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting). 1) The capture system: The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms: - Directly from their clinic; or - Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients 2) The recapture system: The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding	The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3). The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor. The structure is C##.# M####/##, where: - C##.# specifies the primary site - M#### specifies the histology - /## specifies the behavior and the grade of the tumor
Reporting form	NCR reporting form

ATC	Name	B/G	Ingredients	Dosage	Form	Price
A08AB01	ORLY SLIM	G	Orlistat - 120mg	120mg	Capsule	1,174,518 L.L
A08AB01	UNI-CAL	G	Orlistat - 120mg	120mg	Capsule	1,174,518 L.L
A08AB01	LESSFAT	G	Orlistat - 60mg	60mg	Capsule	1,039,238 L.L
A09AA02	CREON 10,000	B	Pancreatin protease - 600FIP-U, Pancreatin amylase - 8,000FIP-U, Pancreatin lipase - 10,000FIP-U		Capsule	1,835,689 L.L
A09AA02	CREON 25,000	B	Pancreatin protease - 1000FIP-U, Pancreatin amylase - 18000FIP-U, Pancreatin lipase - 25000FIP-U		Capsule	4,598,629 L.L
A10AB01	ACTRAPID	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	752,552 L.L
A10AB01	ACTRAPID	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	752,552 L.L
A10AB01	HUMULIN R U-100	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	701,486 L.L
A10AB01	JUSLINE R	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	401,809 L.L
A10AB04	HUMALOG KWIKPEN	BioTech	Insulin lispro - 100IU/ml	100IU/ml	Injectable solution	3,950,897 L.L
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable solution	637,365 L.L
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable solution	2,126,343 L.L
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable solution	883,480 L.L
A10AB04	HUMALOG	BioTech	Insulin lispro - 100IU/ml	100IU/ml	Injectable suspension	1,988,887 L.L
A10AB04	PROLOG	BioTech	Insulin lispro - 100U/ml	100U/ml	Injectable suspension	1,503,312 L.L
A10AB05	NOVORAPID FLEXPEN	BioTech	Insulin aspart - 100IU/ml	100IU/ml	Injectable solution	3,123,090 L.L
A10AB05	NOVORAPID FLEXPEN	BioTech	Insulin aspart - 100IU/ml	100IU/ml	Injectable solution	3,123,090 L.L
A10AB05	NOVORAPID FLEXPEN	BioTech	Insulin aspart - 100IU/ml	100IU/ml	Injectable solution	3,123,090 L.L
A10AB06	APIDRA SOLOSTAR	BioTech	Insulin glulisine - 100IU/ml	100IU/ml	Injectable solution	3,942,834 L.L
A10AB06	APIDRA	BioTech	Insulin glulisine - 100IU/ml	100IU/ml	Injectable solution	2,221,372 L.L
A10AD01	HUMULIN 70/30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	701,486 L.L
A10AD01	JUSLINE	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	401,809 L.L
A10AD01	MIXTARD 30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	752,552 L.L
A10AD01	MIXTARD 30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	752,552 L.L
A10AD04	HUMALOG MIX 50 KWIKPEN	BioTech	Insulin lispro solution - 50%, Insulin lispro protamine suspension - 50%	100IU/ml	Injectable suspension	3,950,897 L.L
A10AD04	HUMALOG MIX 25 KWIKPEN	BioTech	Insulin lispro solution - 25%, Insulin lispro protamine suspension - 75%	100IU/ml	Injectable suspension	3,950,897 L.L
A10AD05	NOVOMIX 30	BioTech	Insulin aspart - 30%, Insulin aspart protamine - 70%	100IU/ml	Injectable suspension	4,264,012 L.L
A10AD05	NOVOMIX 30	BioTech	Insulin aspart - 30%, Insulin aspart protamine - 70%	100IU/ml	Injectable suspension	4,264,012 L.L
A10AD05	NOVOMIX 30	BioTech	Insulin aspart - 30%, Insulin aspart protamine - 70%	100IU/ml	Injectable suspension	4,264,012 L.L
A10AD06	RYZODEG	BioTech	Insulin degludec - 70%, Insulin aspart - 30%	100IU/ml	Injectable solution	7,058,661 L.L

National Cancer Registry (NCR)